Search research articles

Prahlad V Raninga

4PUBLICATIONS

3CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|May 19, 2026

Redox regulation of EGFR activation by thioredoxin reductase 3 drives resistance to EGFR inhibitors in triple-negative breast cancer.

|Mar 03, 2025

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Prahlad V Raninga, Bijun Zeng, Davide Moi

|Dec 20, 2024

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Prahlad V Raninga, Bijun Zeng, Davide Moi

|Dec 20, 2022

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.

Xue Lu, Yaowu He, Rebecca L Johnston

Pageof 1

Frequent Collaborators

2 joint publications

Chelsea Mayoh

2 joint publications

Kum Kum Khanna

1 joint publications

Marco J Herold

Frequent Collaborators

2 joint publications

Chelsea Mayoh

2 joint publications

Kum Kum Khanna

1 joint publications

Marco J Herold

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use